US76135L3096 - Common Stock
REVELATION BIOSCIENCES INC
NASDAQ:REVB (9/28/2023, 7:10:25 PM)
After market: 0.68 +0 (+0.67%)0.6755
-0.01 (-1.39%)
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California. The company went IPO on 2020-10-08. Its therapeutic candidates are based on the active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include REVTx-300, which is being developed as a potential therapy for the prevention and treatment of acute organ injury and chronic organ disease; REVTx-100, which is being developed for the prevention and treatment of infections, including healthcare-associated bacterial infections resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, which is being developed as a potential intranasal therapy that is administered with a traditional commercially available intramuscular (IM) vaccine, and REVTx-99b, which is being developed as a treatment for food allergies.
REVELATION BIOSCIENCES INC
4660 Lajolla Village Drive, Suite 100
San Diego CALIFORNIA
P: 16508003717.0
Employees: 14
Website: https://www.revbiosciences.com/
Here you can normally see the latest stock twits on REVB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: